À compter du 1er décembre 2023, l’accès à POEMs et à Essential Evidence Plus ne fera plus partie des avantages offerts aux membres de l’AMC.
Question clinique
In immunocompromised patients with acute respiratory failure, does the use of high-flow oxygen therapy decrease mortality?
L’Essentiel
High-flow oxygen therapy in immunocompromised patients with acute hypoxemic respiratory failure does not reduce deaths nor improve other patient-centered outcomes. 1b-
Référence
Plan de l'etude: Randomized controlled trial (nonblinded)
Financement: Government
Cadre: Inpatient (ICU only)
Sommaire
In this multicenter French trial, investigators recruited immunocompromised adult patients in the intensive care unit (ICU) with acute hypoxemic respiratory failure who were requiring 6 liters per minute or greater oxygen flow. Using concealed allocation, patients were randomized to receive either high-flow oxygen therapy (n = 389) or standard oxygen therapy (n = 389) during the ICU stay. In the high-flow group, oxygen was initiated via nasal cannula at 50 liters per minute with the flow rate and fraction of inspired oxygen titrated to achieve pulse oximetry of 95% or greater. In the standard group, oxygen was delivered via nasal cannula or mask with the same goal. Patients in the 2 groups had similar baseline characteristics. Cancer was the most common cause of immunosuppression and pneumonia was the most common cause of respiratory failure. In the intention-to-treat analysis, no significant difference was detected in 28-day mortality (35.6% in high-flow group vs 36.1% in standard group; P = .94). The need for mechanical ventilation, comfort and dyspnea scores, number of ICU-acquired infections, and ICU or hospital lengths of stay also did not differ.
Reviewer
Nita Shrikant Kulkarni, MD
Assistant Professor in Hospital Medicine
Northwestern University
Chicago, IL